Could a multiple sclerosis drug sharpen memory in depression?
NCT ID NCT06751784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether fampridine, a drug used for walking problems in multiple sclerosis, can improve working memory in people with mild to moderate depression. About 38 adults will receive both fampridine and a placebo in random order to see if the drug helps them perform better on memory tasks. The goal is to find a new way to treat cognitive issues that often come with depression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fampridine (a potassium channel blocker)
What this could lead to
If it works, this could point toward a treatment for memory problems in people with depression.
What could go wrong
This is a small early-phase trial with only 38 people. It may not show a clear benefit, and fampridine can cause side effects like dizziness or seizures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences
RECRUITINGBasel, Canton of Basel-City, 4055, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••